Last reviewed · How we verify
Adlumiz (ANAMORELIN)
Adlumiz (Anamorelin) is a small molecule growth hormone secretagogue receptor type 1 agonist developed by ONO PHARMACEUTICAL Co., Ltd. It works by binding to the growth hormone secretagogue receptor type 1, stimulating the release of growth hormone, which helps to increase appetite and muscle mass. Adlumiz is approved to treat cancer cachexia, a condition characterized by weight loss and muscle wasting in patients with cancer. The commercial status of Adlumiz is patented, and it is currently owned by ONO PHARMACEUTICAL Co., Ltd. Key safety considerations include potential gastrointestinal side effects and interactions with other medications.
At a glance
| Generic name | ANAMORELIN |
|---|---|
| Sponsor | ONO PHARMACEUTICAL Co., Ltd |
| Target | Growth hormone secretagogue receptor type 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Cancer cachexia
Common side effects
Key clinical trials
- Anamorelin Study for Advanced Pancreatic Cancer (PHASE2)
- Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors (PHASE2)
- Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer (PHASE2,PHASE3)
- A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- Effect of a Ghrelin Receptor Agonist on Muscle and Bone (PHASE1)
- The Role of Ghrelin in Cancer Cachexia (PHASE2)
- Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adlumiz CI brief — competitive landscape report
- Adlumiz updates RSS · CI watch RSS
- ONO PHARMACEUTICAL Co., Ltd portfolio CI